The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List


Thu, Jan 23, 8:46 AM, Zacks
Ventrus Biosciences (VTUS) Jumps: Stock Rises 10.9% - Tale of the Tape
Ventrus Biosciences was a big mover last session, with shares rising nearly 11%.

Fri, Dec 27, 8:39 AM, Zacks
Ventrus Biosciences (VTUS) Jumps: Stock Up 6.8% - Tale of the Tape
Ventrus Biosciences Inc. was a big mover last session, as its shares rose around 7% on the day.

Ventrus Biosciences Inc. (VTUS)

Ventrus Biosciences is a development stage pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders, specifically anal disorders. Co.'s product candidate portfolio consists of two in-licensed late-stage drugs: VEN 307 (topical diltiazem), which is intended to treat pain associated with anal fissures; and VEN 308 (topical phenylephrine), which is intended to treat fecal incontinence. These candidates are two molecules that were previously approved and as of Dec 31 2012, were marketed for other indications and that have been formulated into Co.'s topical treatments for these new gastrointestinal indications.

Company Name:  Ventrus Biosciences Inc.
Sector:  Drugs & Pharmaceuticals
April 18, 2014    4:50 PM Eastern

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Trade VTUS Now:

Hold (2.00 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Ventrus Biosciences Inc. (VTUS) Page | The Online Investor | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.